Intimation of update on Acquisition under Regulation 30 of SEBI (LODR) Regulation, 2015
Awaiting price reaction for this filing.
Authum Investment & Infrastructure has acquired 39,27,000 shares (3.43% voting rights on a fully diluted basis) in OneSource Specialty Pharma Limited, a listed pharma CDMO (formerly Stelis Biopharma). The shares were acquired from Devicam Capital LLP and Pronomz Ventures LLP on June 13, 2025 via a commercial transaction, with a fair market value of Rs. 2,028 per share, totaling about Rs. 796.4 crores. OneSource Specialty has a net worth of Rs. 5,880 crores and posted turnover of Rs. 1,444.8 crores in FY25, up sharply from Rs. 41 crores in FY23. The acquisition is not a related party transaction and required no regulatory approvals.
This is a sizeable Rs. 796+ crore equity deployment into a listed pharma company for Authum, signaling a strategic stake-building in a fast-growing CDMO. For OneSource Specialty shareholders, it brings in a new significant institutional holder, though the 3.43% stake is below the SEBI open-offer threshold so no mandatory offer is triggered.